Item request has been placed!

Item request cannot be made.

Processing Request

Search Results

Display Settings

Results per page: 10

Sort By: Relevance

Filter

Your Filters

Subject : human health sciences

Reset filters

Item request has been placed!

Item request cannot be made.

Processing Request

Academic Journal

Tofacitinib De-escalation Strategy in Ulcerative Colitis: Is It the End of the Story?

Authors : Guillo, Lucas; Peyrin-Biroulet, Laurent; Louis, Edouard

Subjects: Colitis; Ulcerative/drug therapy; Humans

Source: Journal of Crohn's & colitis, 15 (7), 1087-1088 (2021)

Record details

Academic Journal

Efficacy and safety of niraparib as maintenance treatment in older patients (≥ 70 years) with recurrent ovarian cancer: Results from the ENGOT-OV16/NOVA trial.

Authors : Fabbro, Michel; Moore, Kathleen N; Dørum, Anne

Subjects: Niraparib; Older patients; Ovarian cancer

Source: Gynecologic Oncology, 152 (3), 560 - 567 (2019-03)

Record details

Academic Journal

Inhibitors of cannabinoid receptors and glucose metabolism.

Authors : Scheen, André; Paquot, Nicolas

Subjects: Animals; Blood Glucose/metabolism; Diabetes Mellitus

Source: Current Opinion in Clinical Nutrition and Metabolic Care, 11 (4), 505-11 (2008)

Record details

Academic Journal

Inhibition des recepteurs CB1 et metabolisme du glucose: rimonabant dans le diabete de type 2. ; CB1 receptor inhibition and glucose metabolism: role of rimonabant in type 2 diabetes

Authors : Scheen, André; Paquot, Nicolas; Van Gaal, Luc F

Subjects: Blood Glucose/metabolism; Diabetes Mellitus; Type 2/drug therapy/metabolism

Source: Revue Médicale Suisse, 4 (168), 1812-7 (2008)

Record details

Academic Journal

Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program.

Authors : Van Gaal, Luc; Pi-Sunyer, Xavier; Despres, Jean-Pierre

Subjects: Cannabinoids/antagonists & inhibitors; Cardiovascular Diseases/epidemiology/prevention & control; Clinical Trials

Source: Diabetes Care, 31 Suppl 2, S229-40 (2008)

Record details

Academic Journal

Effets cardio-metaboliques du rimonabant chez le sujet obese ou en surpoids avec dyslipidemie ou diabete de type 2. ; Cardiometabolic effects of rimonabant in obese/overweight subjects with dyslipidaemia or type 2 diabetes

Authors : Scheen, André; Van Gaal, L. F.

Subjects: Anti-Obesity Agents/therapeutic use; Bradykinin/antagonists & inhibitors; Cannabinoids/antagonists & inhibitors

Source: Revue Médicale de Liège, 62 (2), 81-5 (2007)

Record details

Academic Journal

Rimonabant as an adjunct therapy in overweight/obese patients with type 2 diabetes.

Authors : Scheen, André; Van Gaal, Luc F

Subjects: Chemotherapy; Adjuvant; Diabetes Mellitus

Source: European Heart Journal, 28 (11), 1401-2; author reply 1402 (2007)

Record details

Academic Journal

Cannabinoid-1 receptor antagonists in type-2 diabetes.

Authors : Scheen, André

Subjects: Animals; Clinical Trials as Topic; Diabetes Mellitus

Source: Best Practice and Research. Clinical Endocrinology and Metabolism, 21 (4), 535-53 (2007)

Record details

Academic Journal

Le rimonabant ameliore le profit de risque cardio-metabolique chez le sujet obese ou en surpoids: synthese des etudes 'RIO'. ; Rimonabant improves cardiometabolic risk profile in obese or overweight subjects: overview of RIO studies

Authors : Scheen, André; Van Gaal, L. G.; Despres, J. P.

Subjects: Anti-Obesity Agents/therapeutic use; Humans; Metabolic Syndrome X/prevention & control

Source: Revue Médicale Suisse, 2 (76), 1916-23 (2006)

Record details

Academic Journal

Inhibition des recepteurs CB1 et metabolisme du glucose: rimonabant dans le diabete de type 2.

Authors : Scheen, André; Paquot, Nicolas; Van Gaal, Luc F

Subjects: Blood Glucose/metabolism; Diabetes Mellitus, Type 2/drug therapy/metabolism; Humans

Source: Revue Médicale Suisse, 4 (168), 1812-7 (2008)

Record details

Search Results

Your Filters

Tofacitinib De-escalation Strategy in Ulcerative Colitis: Is It the End of the Story?

Efficacy and safety of niraparib as maintenance treatment in older patients (≥ 70 years) with recurrent ovarian cancer: Results from the ENGOT-OV16/NOVA trial.

Inhibitors of cannabinoid receptors and glucose metabolism.

Inhibition des recepteurs CB1 et metabolisme du glucose: rimonabant dans le diabete de type 2. ; CB1 receptor inhibition and glucose metabolism: role of rimonabant in type 2 diabetes

Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program.

Effets cardio-metaboliques du rimonabant chez le sujet obese ou en surpoids avec dyslipidemie ou diabete de type 2. ; Cardiometabolic effects of rimonabant in obese/overweight subjects with dyslipidaemia or type 2 diabetes

Rimonabant as an adjunct therapy in overweight/obese patients with type 2 diabetes.

Cannabinoid-1 receptor antagonists in type-2 diabetes.

Le rimonabant ameliore le profit de risque cardio-metabolique chez le sujet obese ou en surpoids: synthese des etudes 'RIO'. ; Rimonabant improves cardiometabolic risk profile in obese or overweight subjects: overview of RIO studies

Inhibition des recepteurs CB1 et metabolisme du glucose: rimonabant dans le diabete de type 2.

Contact

Follow us